Biotie - Articles and news items

Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease

Industry news / 21 July 2015 / Victoria White

A Phase 3 study of tozadenant in patients with Parkinson’s disease experiencing levodopa related end-of-dose “wearing-off” has started…

Biotie Logo

Biotie provides portfolio update on tozadenant

Industry news / 20 February 2015 / Biotie

Biotie has announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson’s disease (PD)…

Biotie Logo

Biotie’s BTT1023 receives positive opinion for Orphan Drug Designation from COMP

Industry news / 17 February 2015 / Biotie

COMP has issued a positive opinion recommending orphan drug designation for Biotie’s BTT1023 for the treatment of primary sclerosing cholangitis (PSC)…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...